Trial · NCT05697770
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MAKE30 score | 30 days or at hospital discharge (whichever occurs first) | The primary outcome is MAKE30 from the date of randomisation. MAKE30 is defined as a composite of death from any cause, receipt of RRT, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline), all censored at hospital discharge or 30 days, whichever occurs first. |
| Secondary | 30-day in-hospital mortality | 30 days or at hospital discharge (whichever occurs first) | All-cause in-hospital mortality at day 30 |
| Secondary | Receipt of renal replacement therapy in the first 30 days | 30 days or at hospital discharge (whichever occurs first) | Receipt of renal replacement therapy in the first 30 days |
| Secondary | Persistent renal dysfunction | 30 days or at hospital discharge (whichever occurs first) | Defined as an elevation of the creatinine level to ≥ 200% of baseline |
| Secondary | Renal replacement therapy dependence at day 30 | 30 days or at hospital discharge (whichever occurs first) | Defined by the receipt of any form of renal replacement therapy within ± 10 days of the 30-day time point following randomisation |
| Secondary | ICU mortality | 30 days or at hospital discharge (whichever occurs first) | All-cause ICU mortality at day 30 |
| Secondary | Hospital mortality | 90 days or at hospital discharge (whichever occurs first) | All-cause hospital mortality at day 90 |
| Secondary | 90-day in-hospital mortality | 90 days or at hospital discharge (whichever occurs first) | All-cause mortality at day 90 |
| Other | Recurrence of metabolic acidosis in the first 7 days after randomization | 7 days after randomization | Defined as pH \< 7.30, BE ≤ -4 mEq/L and PaCO2 ≤ 45 mmHg |
| Other | Incidence and the maximum stage of AKI in the first 7 days after randomization | 7 days after randomization | According to KDIGO criteria |
| Other | Vasopressor-free days at day 30 | 30 days or at hospital discharge (whichever occurs first) | Defined as 30 - days receiving a continuous infusion of vasopressor \[at any time and for any duration\]; non-survivors at day 30 will receive 0 |
| Other | Renal replacement therapy-free days at day 30 | 30 days or at hospital discharge (whichever occurs first) | Defined as 30 - days receiving RRT; non-survivors at day 30 will receive 0 |
| Other | ICU-free days at day 30 | 30 days or at hospital discharge (whichever occurs first) | Defined as 30 - ICU length of stay; non-survivors at day 30 will receive 0 |
| Other | Hospital-free days at day 90 | 90 days or at hospital discharge (whichever occurs first) | Defined as 90 -hospital length of stay; non-survivors at day 90 will receive 0 |
| Other | Health-Related Quality of Life | 180 days | EQ-5D-5L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05697770/registered